Related references
Note: Only part of the references are listed.Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease
Jacob E. Ollech et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission
Jurij Hanzel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease
Samuel Raimundo Fernandes et al.
INFLAMMATORY BOWEL DISEASES (2020)
Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study
Johan Burisch et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy
Uri Kopylov et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease
Ninon Soufflet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates
Bram Verstockt et al.
JOURNAL OF CROHNS & COLITIS (2019)
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
Pieter Hindryckx et al.
JOURNAL OF CROHNS & COLITIS (2018)
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2018)
Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients
Marla C. Dubinsky et al.
AAPS JOURNAL (2017)
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease
Robert Battat et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Review article: dose optimisation of infliximab for acute severe ulcerative colitis
P. Hindryckx et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
Johannan F. Brandse et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies
Casper Steenholdt et al.
INFLAMMATORY BOWEL DISEASES (2016)
Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease
Clare Moore et al.
JOURNAL OF CROHNS & COLITIS (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease - a SONIC post hoc analysis
J. -F. Colombel et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Epidemiology and risk factors for IBD
Ashwin N. Ananthakrishnan
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2014)
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial
Casper Steenholdt et al.
GUT (2014)
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
Freddy Cornillie et al.
GUT (2014)
A Nationwide 2010-2012 Analysis of U.S. Health Care Utilization in Inflammatory Bowel Diseases
Welmoed K. van Deen et al.
INFLAMMATORY BOWEL DISEASES (2014)
Serum Adalimumab Concentration and Clinical Remission in Patients with Crohn's Disease
Yi-Lin Chiu et al.
INFLAMMATORY BOWEL DISEASES (2013)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
Natalie A. Molodecky et al.
GASTROENTEROLOGY (2012)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Share Paper
